MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 84 filers reported holding MARINUS PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 1.93 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $271,500 | +12.4% | 25,000 | -28.6% | 0.00% | -20.0% |
| Q1 2023 | $241,500 | +73.4% | 35,000 | 0.0% | 0.01% | +66.7% |
| Q4 2022 | $139,300 | -40.2% | 35,000 | 0.0% | 0.00% | -25.0% |
| Q3 2022 | $233,000 | +37.9% | 35,000 | 0.0% | 0.00% | -20.0% |
| Q2 2022 | $169,000 | -48.3% | 35,000 | 0.0% | 0.01% | -54.5% |
| Q1 2022 | $327,000 | +10.1% | 35,000 | +40.0% | 0.01% | +37.5% |
| Q4 2021 | $297,000 | +4.2% | 25,000 | 0.0% | 0.01% | -11.1% |
| Q3 2021 | $285,000 | -38.4% | 25,000 | 0.0% | 0.01% | -52.6% |
| Q2 2021 | $463,000 | +22.2% | 25,000 | 0.0% | 0.02% | +11.8% |
| Q1 2021 | $379,000 | +146.1% | 25,000 | +100.0% | 0.02% | +13.3% |
| Q4 2020 | $154,000 | -97.8% | 12,500 | -97.7% | 0.02% | -97.4% |
| Q3 2020 | $6,890,000 | – | 538,300 | – | 0.57% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 2,145,337 | $17,269,963 | 7.70% |
| Bleichroeder LP | 1,872,463 | $15,073,327 | 3.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,204,942 | $41,899,783 | 2.26% |
| Opaleye Management Inc. | 584,000 | $4,701,200 | 1.53% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $11,520,017 | 1.29% |
| Cormorant Asset Management, LP | 2,625,000 | $21,131,250 | 1.23% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 290,000 | $2,337,400 | 0.79% |
| Ikarian Capital, LLC | 746,069 | $6,005,856 | 0.72% |
| Eventide Asset Management | 4,529,997 | $36,466,476 | 0.66% |
| Altium Capital Management LP | 125,033 | $1,006,516 | 0.52% |